Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients

NCT01345916 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

932

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: CHF 1535 100/6 NEXT DPI® 2 months
DRUG: CHF 1535 100/6 pMDI 2 months
DRUG: BDP DPI 2 months

Sponsor

Chiesi Farmaceutici S.p.A.